C.O. Truxton, Inc. Recalls Amitriptyline and Phenobarbital Tablets Due to Potential Label Mix-Up

C.O. Truxton, Inc. is expanding their 04/21/2017 voluntary recall, as a precaution to include the following C.O. Truxton, Inc. products, registered NDC numbers and corresponding lot numbers, to the consumer/user level. C.O. Truxton has not received any complaints for the products listed below; however, due to the initial recall resulting from a label mix-up error, out of an abundance of caution, they are recalling all products that were repackaged into a Truxton Incorporated label.

Product Name NDC Code Lot Number Expiration
Phenobarbital Tablets, USP 15mg (1000) 0463-6160-10 70915A August 2017
H15A55 November 2017
70952A November 2017
71162A October 2018
Phenobarbital Tablets, USP 30mg (1000) 0463-6145-10 70926A November 2017
70981A January 2018
H15A59 August 2018
Phenobarbital Tablets, USP 60mg (1000) 0463-6151-10 70881A July 2017
H15A68 January 2018
70980A February 2018
71416A May 2020
Phenobarbital Tablets, USP 100mg (100) 0463-6152-01 70989A February 2018
70973A January 2018
Phenobarbital Tablets, USP 100mg (1000) 0163-6152-10 70973A January 2018
H15A76 February 2018
71346A December 2019
Phenobarbital Tablets, USP 100mg (1000) 0463-6152-01 70989A February 2018
Amitriptyline Tablets, USP 50mg (100) 0463-6352-10 C0260416A March 2018

If mislabeled, inadvertent exposure to, or overdose of phenobarbital could cause severe intoxication which may lead to cardiogenic shock, renal failure, coma, or death in humans and animals.

If mislabeled, inadvertent exposure to, or overdose of amitriptyline could cause uneven heartbeats, extreme drowsiness, confusion, agitation, vomiting, hallucinations, hot or cold sensations, muscle stiffness, seizures (convulsions), or fainting in humans and animals. C.O. Truxton, Inc. has not received any reports of adverse events related to this recall.

Phenobarbital is indicated for use as a sedative or anticonvulsant and is packaged in the following configurations:

NDC Package Size Strength (mg) Tablet Appearance Side One Tablet Appearance Side Two
0463-6160-10 1000 15 West-ward 445, white Blank, white
0463-6145-10 1000 30 West-ward 450, white Score line, white
0463-6151-10 1000 60 WW 455, white Blank, white
0463-6152-01 100 100 WW 458, white Score line, white
0463-6152-10 1000 100 WW 458, white Score line, white

Amitriptyline is indicated for use as a tricyclic antidepressant and is packaged in the following configuration:

NDC Package Size Strength (mg) Tablet Appearance Side One Tablet Appearance Side Two
0463-6352-10 100 50 2103, beige V, beige

C.O. Truxton, Inc. is notifying all customers on record who purchased the above listed products under Truxton Incorporated label/NDC via US Mail with a recall letter and recall response form. C.O. Truxton, Inc. and is arranging for full credit returns, replacements, etc. of all recalled product. Consumers/distributors/retailers that have recalled product should stop using the product immediately and return their product to the place of purchase.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program online, by regular mail or by fax.

Updated: 2017-05-09 07:00:00

Source: FDA